Steven J. Burakoff

Steven J. Burakoff, MD, is a cancer specialist and the author of both Therepeutic Immunology (2001) and Graft-Vs.-Host Disease: Immunology, Pathophysiology, and Treatment (1990).

Burakoff is the Director of the The Tisch Cancer Institute at Mount Sinai, which was created in 2007 to focus on translational medicine.

Before joining Mount Sinai, he was recruited by NYU to revitalize the research and treatment mission of NYU's Cancer Institute, which during his tenure experienced a 31 percent growth and a 50 percent increase in NCI funding.

He completed a residency in medicine at New York Hospital-Cornell Medical Center and pursued fellowships in immunology at both Rockefeller University and Harvard Medical School.

His brother is the gastroenterologist at Brigham & Women's Hospital in Boston, MA, Robert Burakoff, MD, MPH.

• Harvard Medical School Excellence in Mentoring Award

• Director of The Tisch Cancer Institute at Mount Sinai [1]
• Formerly Laura and Isaac Perlmutter Professor, New York University School of Medicine
• Past Director, New York University Cancer Institute
• Past Director, Skirball Institute of Biomolecular Medicine, New York University School of Medicine
• Past Chair of Pediatric Oncology at the Dana-Farber Cancer Institute
• Formerly Margaret M. Dyson Professor of Pediatrics at the Harvard Medical School
• Former Ted Williams Senior Investigator at the Dana-Farber Cancer Institute
• Former Member, Board of Trustees of the Dana-Farber Cancer Institute
• Board of Directors, Pharmacopeia Drug Discovery, Inc.

• Skirball Institute - Steven Burakoff Laboratory retrieved April 28, 2008
• Pharmacopeia: Board of Directors retrieved April 28, 2008

• Lehigh University with a Bachelor of Science degree
• Master’s degree from Queens College
• M.D. from Albany Medical College
• Honorary Master’s of Science Degree from Harvard University

Books

• Strom TB, Austen KF, Burakoff SJ. Therepeutic Immunology. Wiley-Blackwell, 2001 ISBN 0-632-04359-8
• Ferrara JLM, Deeg HJ, Burakoff SJ. Graft-Vs.-Host Disease: Immunology, Pathophysiology, and Treatment. Marcel Dekker, 1990 ISBN 0-8247-9728-0

Other publications (partial list)

• Interleukin-3 (IL-3)-induced c-fos activation is modulated by Gab2-calcineurin interaction. Pyarajan S, Matejovic G, Pratt JC, Baksh S, Burakoff SJ. J Biol Chem. 2008 PMID 18586679
• Lysine 144, a ubiquitin attachment site in HIV-1 Nef, is required for Nef-mediated CD4 down-regulation. Jin YJ, Cai CY, Zhang X, Burakoff SJ. J Immunol. 2008 PMID 18523251
• Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway. Sawasdikosol S, Pyarajan S, Alzabin S, Matejovic G, Burakoff SJ. The journal of biological chemistry, 2007 PMID 17895239
• From bytes to bedside: data integration and computational biology for translational cancer research. Mathew JP, Taylor BS, Bader GD, Pyarajan S, Antoniotti M, Chinnaiyan AM, Sander C, Burakoff SJ, Mishra B. PLoS computational biology, 2007 PMID 17319736
• A CD8/Lck transgene is able to drive thymocyte differentiation. Fragoso RC, Pyarajan S, Irie HY, Burakoff SJ. Journal of immunology, 2006 PMID 17056525
• HIV Nef-mediated CD4 down-regulation is adaptor protein complex 2 dependent. Jin YJ, Cai CY, Zhang X, Zhang HT, Hirst JA, Burakoff SJ. Journal of immunology, 2005 PMID 16116206
• CD4 phosphorylation partially reverses Nef down-regulation of CD4. Jin YJ, Zhang X, Boursiquot JG, Burakoff SJ. Journal of immunology, 2004 PMID 15494497
• Nicotine activates nuclear factor of activated T cells c2 (NFATc2) and prevents cell cycle entry in T cells. Frazer-Abel AA, Baksh S, Fosmire SP, Willis D, Pierce AM, Meylemans H, Linthicum DS, Burakoff SJ, Coons T, Bellgrau D, Modiano JF. The journal of pharmacology and experimental therapeutics, 2004 PMID 15231866
• SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness. Friedman JS, Lopez MF, Fleming MD, Rivera A, Martin FM, Welsh ML, Boyd A, Doctrow SR, Burakoff SJ. Blood, 2004 PMID 15205258
• Fratricide of CD8+ cytotoxic T lymphocytes is dependent on cellular activation and perforin-mediated killing. Su MW, Pyarajan S, Chang JH, Yu CL, Jin YJ, Stierhof YD, Walden P, Burakoff SJ. European journal of immunology, 2004 PMID 15307178
• Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model. Friedman JS, Alpdogan O, van den Brink MR, Liu C, Hurwitz D, Boyd A, Kupper TS, Burakoff SJ. Journal of the American society of blood and marrow transplantation, 2004 PMID 15205666
• Rapamycin-resistant proliferation of CD8+ T cells correlates with p27kip1 down-regulation and bcl-xL induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity. Slavik JM, Lim DG, Burakoff SJ, Hafler DA., Journal of biological chemistry, 2004 PMID 14573608